Vectibix (Panitumumab)
Anti-EGFR monoclonal antibody for metastatic colorectal cancer with wild-type RAS
Vectibix (panitumumab) is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is used to treat metastatic colorectal cancer in adults whose tumours have been confirmed as wild-type RAS through validated testing. Vectibix may be used alone or in combination with certain chemotherapy regimens.
Quick Facts
Key Takeaways
- Vectibix is only effective in metastatic colorectal cancer patients with confirmed wild-type RAS tumours – RAS testing is mandatory before treatment
- Administered as an intravenous infusion every 2 weeks at a dose of 6 mg/kg body weight, typically over 60 minutes
- Skin reactions occur in approximately 94% of patients and are the most characteristic side effect – proactive skin care is essential
- Must not be combined with bevacizumab or IFL chemotherapy, and must not be used with oxaliplatin in RAS-mutant patients
- Regular monitoring of blood electrolytes (magnesium, calcium, potassium) is required during and for 8 weeks after treatment
What Is Vectibix and What Is It Used For?
Quick Answer: Vectibix (panitumumab) is a targeted cancer treatment used for metastatic colorectal cancer (cancer that has spread from the colon or rectum). It works by blocking a protein called EGFR on the surface of cancer cells, preventing them from growing and dividing. It is only used in patients whose tumours have wild-type RAS.
Vectibix belongs to a class of medicines known as monoclonal antibodies. These are proteins specifically engineered to recognise and attach to unique proteins in the body. In the case of panitumumab, it binds to the epidermal growth factor receptor (EGFR), which is found on the surface of many cancer cells, particularly those in colorectal cancer.
Under normal conditions, growth factors such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) bind to EGFR and activate signalling pathways that promote cell growth, division, and survival. In many colorectal cancers, EGFR is overexpressed, meaning the cancer cells have an abnormally high number of these receptors on their surface. This overexpression contributes to uncontrolled tumour growth, invasion of surrounding tissues, and the formation of new blood vessels to supply the tumour (angiogenesis).
Panitumumab works by binding to the extracellular domain of EGFR with high affinity, effectively blocking EGF and TGF-alpha from activating the receptor. This interrupts the downstream signalling cascades, including the RAS/RAF/MEK/ERK and PI3K/AKT pathways, which are critical for cancer cell proliferation. By inhibiting these pathways, panitumumab slows tumour growth, promotes cancer cell death (apoptosis), and reduces the production of proteins involved in angiogenesis and metastasis.
A critical requirement for Vectibix therapy is that the patient's tumour must have wild-type RAS (no mutations in the KRAS or NRAS genes). When RAS genes are mutated, the signalling pathway downstream of EGFR is permanently activated, regardless of whether EGFR is blocked. In such cases, panitumumab provides no clinical benefit and may even be harmful when combined with certain chemotherapy regimens. Therefore, RAS mutation testing using a validated method is mandatory before initiating Vectibix treatment.
Vectibix is approved for the treatment of adult patients with metastatic colorectal cancer (mCRC) with wild-type RAS, either as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens, or in combination with FOLFOX (first-line) or FOLFIRI (second-line) chemotherapy.
What Should You Know Before Taking Vectibix?
Quick Answer: Vectibix must not be used if you have a history of interstitial pneumonitis or pulmonary fibrosis, or if your tumour has mutant RAS or unknown RAS status when combined with oxaliplatin-based chemotherapy. Important precautions include monitoring for skin reactions, electrolyte imbalances, and eye problems.
Contraindications
There are several situations in which Vectibix must not be used. Understanding these contraindications is essential for patient safety and optimal treatment outcomes.
- Hypersensitivity: Do not use Vectibix if you are allergic to panitumumab or any of the other ingredients (sodium chloride, sodium acetate trihydrate, acetic acid, water for injections)
- Interstitial lung disease: Vectibix is contraindicated in patients who currently have or have previously had interstitial pneumonitis (lung inflammation causing cough and breathing difficulties) or pulmonary fibrosis (scarring and thickening of the lungs)
- RAS-mutant tumours with oxaliplatin: Vectibix must not be used in combination with oxaliplatin-based chemotherapy if your tumour has mutant RAS or if your RAS mutation status is unknown
Warnings and Precautions
Several important warnings and precautions should be considered before and during treatment with Vectibix. Your healthcare team will monitor you closely for these potential complications.
Skin reactions are the most frequently observed adverse effects of Vectibix, affecting approximately 94% of patients. These reactions may include acne-like rash, dry skin, itching, redness, and skin fissures. While most are mild to moderate, severe skin reactions can occur. If symptoms worsen or become intolerable, your doctor may adjust the dose or temporarily discontinue treatment. Severe skin infections or fever related to skin reactions may necessitate permanent discontinuation of Vectibix.
Sun exposure should be limited during Vectibix treatment, as sunlight can exacerbate skin reactions. Your doctor may recommend using a moisturiser, sunscreen with SPF greater than 15, topical steroid cream, and/or oral antibiotics as part of a proactive skin management programme to prevent and manage dermatologic toxicity.
Electrolyte monitoring is essential during Vectibix treatment. Before starting therapy, your doctor will check blood levels of magnesium, calcium, and potassium. These electrolytes will be monitored regularly throughout treatment and for up to 8 weeks after the last dose. Low levels (hypomagnesaemia, hypocalcaemia, hypokalaemia) are common and may require supplementation.
Diarrhoea may occur during treatment and can lead to significant fluid loss and dehydration, which may impair kidney function. Report severe diarrhoea to your healthcare team promptly so that appropriate supportive care can be initiated.
Eye problems should be monitored carefully. Inform your doctor if you use contact lenses or have a history of dry eyes, corneal inflammation, or corneal ulcers. Seek immediate medical attention if you develop acute or worsening eye redness, pain, increased tearing, blurred vision, or light sensitivity, as these may indicate serious corneal complications requiring urgent treatment.
In rare cases, severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis may occur. If you develop blisters on your skin, mouth, eyes, or genitals, seek immediate medical attention. These are potentially life-threatening conditions that require urgent specialist care.
Pregnancy and Breastfeeding
Vectibix has not been studied in pregnant women. Based on its mechanism of action, it may cause harm to the developing foetus or affect the ability to maintain pregnancy. EGFR plays an important role in embryonic development, and blocking it with panitumumab could interfere with normal foetal growth.
Women of childbearing potential must use effective contraception during treatment with Vectibix and for at least 2 months after the last dose. It is crucial to inform your oncologist immediately if you become pregnant or suspect you may be pregnant during treatment.
Breastfeeding is not recommended during Vectibix treatment and for 2 months after the last dose. It is unknown whether panitumumab is excreted in human breast milk, but given its potential for serious adverse effects in nursing infants, the decision to discontinue breastfeeding or discontinue treatment should be made in consultation with your oncologist.
The effects of panitumumab on fertility in humans have not been established. Patients who are concerned about fertility should discuss options for fertility preservation with their healthcare team before starting treatment.
How Does Vectibix Interact with Other Drugs?
Quick Answer: Vectibix must not be combined with bevacizumab or the IFL chemotherapy regimen due to increased toxicity and decreased survival. It should not be used with oxaliplatin-based chemotherapy in patients with RAS-mutant tumours or unknown RAS status.
Drug interactions with Vectibix are clinically significant and can have serious consequences. The most critical interactions involve other anti-cancer agents. Unlike small-molecule drugs that are metabolised by liver enzymes, panitumumab is a monoclonal antibody that is cleared through proteolytic degradation, which limits traditional pharmacokinetic drug interactions. However, pharmacodynamic interactions with other biologics and chemotherapy regimens are well-documented and clinically important.
Major Interactions
| Interacting Drug | Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Bevacizumab | Contraindicated | Increased toxicity and decreased overall survival when combined | Must not be co-administered |
| IFL regimen (irinotecan, fluorouracil, leucovorin) | Contraindicated | Increased rate of severe diarrhoea and other adverse events | Must not be co-administered |
| Oxaliplatin-based chemo (in RAS-mutant patients) | Contraindicated | Decreased progression-free survival and overall survival in RAS-mutant patients | Contraindicated in mutant RAS or unknown RAS status |
Approved Combinations
Vectibix may be safely combined with the following chemotherapy regimens in patients with confirmed wild-type RAS metastatic colorectal cancer:
- FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) – approved for first-line treatment
- FOLFIRI (5-fluorouracil, leucovorin, irinotecan) – approved for second-line treatment
Always inform your oncologist and pharmacist about all medications you are currently taking, including prescription medicines, over-the-counter drugs, herbal supplements, and vitamins. This ensures that any potential interactions can be identified and managed appropriately.
What Is the Correct Dosage of Vectibix?
Quick Answer: The recommended dose of Vectibix is 6 mg/kg body weight given as an intravenous infusion every two weeks. The infusion typically takes about 60 minutes, or 90 minutes for doses exceeding 1000 mg. It is administered in a clinical setting under physician supervision.
Adults
Standard Adult Dosing
The recommended dose is 6 mg per kilogram of body weight administered once every 2 weeks (Q2W).
- Administered as an intravenous infusion via an infusion pump
- Standard infusion time: approximately 60 minutes
- Doses exceeding 1000 mg: infusion time extended to approximately 90 minutes
- Must be administered through a low protein-binding in-line filter (0.2 or 0.22 micrometre pore size)
- May be given through peripheral or central venous access
Vectibix is diluted in 0.9% sodium chloride solution before administration. The total volume is typically 100 ml, or 150 ml for doses exceeding 1000 mg. The final concentration must not exceed 10 mg/ml. Healthcare professionals use aseptic technique throughout the preparation and administration process.
| Body Weight | Dose (6 mg/kg) | Infusion Volume | Infusion Time |
|---|---|---|---|
| 60 kg | 360 mg | 100 ml | ~60 minutes |
| 80 kg | 480 mg | 100 ml | ~60 minutes |
| 100 kg | 600 mg | 100 ml | ~60 minutes |
| 120 kg | 720 mg | 100 ml | ~60 minutes |
| >167 kg | >1000 mg | 150 ml | ~90 minutes |
Children
Vectibix is not indicated for use in children and adolescents under 18 years of age. The safety and efficacy of panitumumab in the paediatric population have not been established. Metastatic colorectal cancer is exceedingly rare in children, and no clinical trials have evaluated Vectibix in this age group.
Elderly
No specific dose adjustment is required for elderly patients based on age alone. However, patients older than 65 years may have a reduced ability to tolerate treatment, particularly when Vectibix is combined with chemotherapy. Your oncologist will carefully evaluate your overall health status, organ function, and presence of comorbidities before determining whether you are a suitable candidate for Vectibix therapy and selecting the most appropriate combination regimen.
Dose Modifications
Dose modifications or temporary treatment interruptions may be necessary based on the severity of adverse reactions, particularly skin toxicity and infusion reactions. Your oncologist will follow established dose modification guidelines:
- Grade 3 skin toxicity: Withhold Vectibix; resume at reduced dose once toxicity improves to Grade 2 or lower
- Grade 3 or 4 infusion reactions: Permanently discontinue Vectibix
- Severe or life-threatening skin reactions (Grade 4): Permanently discontinue Vectibix
Overdose
There is no specific antidote for panitumumab overdose. Doses up to 9 mg/kg have been evaluated in clinical studies. In case of overdose, the patient should be monitored for any signs or symptoms of adverse reactions, and appropriate supportive treatment should be initiated immediately. The most likely consequences of overdose would be an increase in the severity and frequency of known adverse effects, particularly skin reactions and electrolyte imbalances.
What Are the Side Effects of Vectibix?
Quick Answer: The most common side effects of Vectibix affect the skin (occurring in approximately 94% of patients), including acne-like rash, dry skin, and itching. Other frequent side effects include fatigue, nausea, diarrhoea, low magnesium levels, and eye inflammation. Serious but rare side effects include severe infusion reactions and interstitial lung disease.
Like all medicines, Vectibix can cause side effects, although not everyone experiences them. The side effect profile of Vectibix is largely related to its mechanism of action – EGFR is expressed not only on cancer cells but also on normal cells in the skin, gastrointestinal tract, and other tissues. Understanding the frequency and nature of these side effects helps patients and caregivers recognise them early and seek appropriate management.
Infusion Reactions
Infusion reactions may occur during or after Vectibix administration. Mild to moderate reactions occur in up to 1 in 100 patients, while severe reactions occur in approximately 1 in 1,000 patients. Symptoms may include headache, rash, itching, flushing, swelling of the face and throat, rapid heartbeat, sweating, nausea, dizziness, and difficulty breathing. In very rare cases, severe infusion reactions can be life-threatening. If any of these symptoms occur, notify your healthcare team immediately. The infusion rate may be slowed or treatment discontinued.
In very rare instances, serious allergic reactions (anaphylaxis) with symptoms similar to infusion reactions have occurred more than 24 hours after treatment and have been fatal. Seek immediate medical attention if you experience symptoms of an allergic reaction, including breathing difficulties, chest tightness, choking sensation, dizziness, or fainting.
Skin Reactions
Skin reactions are the hallmark side effect of EGFR inhibitors, affecting approximately 94 out of 100 patients treated with Vectibix. These are generally mild to moderate in severity. The rash typically resembles acne and most commonly affects the face, upper chest, and back, although it can appear anywhere on the body. Some rashes may be red, itchy, and flaky, and in severe cases can lead to infected wounds requiring medical or surgical treatment.
In rare cases, patients may develop blisters on the skin, in the mouth, eyes, and genital area. This may indicate Stevens-Johnson syndrome or toxic epidermal necrolysis, both of which are serious, potentially life-threatening conditions requiring immediate medical intervention. Prolonged sun exposure can worsen skin reactions. Dry skin, skin fissures, and nail bed infections (paronychia) are also commonly reported.
Side Effect Frequency
Very Common
May affect more than 1 in 10 patients
- Skin rash (acne-like), dry skin, itching, skin fissures
- Hair loss (alopecia), mouth sores (stomatitis)
- Diarrhoea, nausea, vomiting, abdominal pain, constipation
- Decreased appetite, weight loss
- Fatigue, fever, weakness (asthenia)
- Peripheral oedema (swelling in arms and legs)
- Back pain, insomnia
- Low red blood cells (anaemia)
- Low magnesium (hypomagnesaemia), low potassium (hypokalaemia)
- Eye inflammation (conjunctivitis)
- Cough, difficulty breathing (dyspnoea)
Common
May affect up to 1 in 10 patients
- Low white blood cells (leucopenia), low calcium, low phosphate, high blood sugar
- Excessive eyelash growth, increased tearing, eye redness, dry eyes
- Skin ulcers, excessive sweating, hand-foot syndrome
- Cellulitis, folliculitis, urinary tract infection
- Nail disorders, brittle nails
- Dehydration, dry mouth, indigestion, rectal bleeding
- Chest pain, chills, rapid heartbeat (tachycardia)
- Pulmonary embolism, deep vein thrombosis, high blood pressure
- Nosebleeds (epistaxis), hot flushes
- Headache, dizziness, anxiety
Uncommon
May affect up to 1 in 100 patients
- Bluish discolouration of skin and mucous membranes (cyanosis)
- Skin necrosis (tissue death)
- Stevens-Johnson syndrome (severe blistering of skin, mouth, eyes, genitals)
- Toxic epidermal necrolysis (severe skin blistering)
- Ulcerative keratitis (corneal ulceration requiring urgent treatment)
- Keratitis (corneal inflammation)
- Eyelid irritation, cracked/dry lips, eye infection, eyelid infection
- Nasal dryness, nail shedding (onycholysis), ingrown nails
- Interstitial lung disease (lung inflammation)
Rare / Very Rare
May affect fewer than 1 in 1,000 patients
- Severe anaphylactic reactions (potentially fatal, may occur >24 hours after infusion)
- Fatal infusion reactions
- Severe interstitial pneumonitis
If you experience any side effects, including those not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Vectibix?
Quick Answer: Vectibix must be stored in a refrigerator at 2–8°C, protected from light, and must not be frozen. After dilution, it should be used immediately or stored at 2–8°C for no more than 24 hours.
Vectibix is stored and handled by healthcare professionals in a clinical setting. However, understanding storage requirements is important for ensuring the integrity and safety of the medication.
- Temperature: Store in a refrigerator at 2°C to 8°C (36°F to 46°F)
- Freezing: Do not freeze. If the solution has been frozen, it must be discarded
- Light protection: Keep in the original packaging to protect from light
- After dilution: Use immediately. If not used immediately, diluted solution may be stored at 2–8°C for a maximum of 24 hours. Diluted solution must not be frozen
- Expiry date: Do not use after the expiry date stated on the label and carton
- Single use only: Vectibix vials are for single use. Discard any unused solution remaining in the vial
Keep this medicine out of the sight and reach of children. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use, as these measures help to protect the environment.
The solution should be colourless and may contain visible translucent to white, amorphous protein particles, which are removed by in-line filtration during administration. Do not administer Vectibix if the solution appears discoloured, cloudy, or contains particulate matter other than the described protein particles.
What Does Vectibix Contain?
Quick Answer: Each millilitre of Vectibix contains 20 mg of panitumumab as the active ingredient. It is available in 5 ml vials (100 mg) and 20 ml vials (400 mg).
Vectibix is supplied as a concentrate for solution for infusion. It is a colourless liquid that may contain visible particles and comes in a glass vial. Each pack contains one vial.
Active Ingredient
- Panitumumab – 20 mg per ml
- 5 ml vial contains 100 mg panitumumab
- 20 ml vial contains 400 mg panitumumab
Inactive Ingredients (Excipients)
- Sodium chloride
- Sodium acetate trihydrate
- Acetic acid (concentrated)
- Water for injections
This medicine contains 3.45 mg sodium (the main component of table salt) per ml. This is equivalent to 0.17% of the recommended maximum daily dietary intake of sodium for an adult. This should be taken into consideration by patients on a controlled sodium diet.
Preparation Information for Healthcare Professionals
Vectibix must be diluted with 0.9% sodium chloride solution for injection using aseptic technique. The vial should not be shaken or handled roughly. A 21-gauge or smaller hypodermical needle should be used to withdraw the required dose. Needle-free devices (such as vial adapters) should not be used. The diluted solution should be mixed gently by inversion, not shaking.
The infusion line must be flushed with sodium chloride solution before and after Vectibix administration to avoid mixing with other medications. Vectibix must be administered through a low protein-binding in-line filter with a 0.2 or 0.22 micrometre pore size via an infusion pump. No incompatibilities have been observed with 0.9% sodium chloride solution in polyvinyl chloride or polyolefin bags.
Frequently Asked Questions About Vectibix
Medical References
This article is based on the following peer-reviewed sources and authoritative guidelines. All medical claims have been verified against international standards.
- European Medicines Agency (EMA). Vectibix – Summary of Product Characteristics. Last updated 2025. Available at: EMA – Vectibix EPAR
- U.S. Food and Drug Administration (FDA). Vectibix (panitumumab) Prescribing Information. Amgen Inc. Reference ID: 5306834.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer. Version 1.2026.
- European Society for Medical Oncology (ESMO). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(1):10–32.
- Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Annals of Oncology. 2014;25(7):1346–1355. doi:10.1093/annonc/mdu141
- Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2010;28(31):4706–4713.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023. Geneva: World Health Organization.
- British National Formulary (BNF). Panitumumab – Drug Monograph. National Institute for Health and Care Excellence (NICE). 2025.
About Our Medical Editorial Team
All medical content on iMedic is created and reviewed by a team of licensed specialist physicians with expertise in oncology, clinical pharmacology, and internal medicine. Our editorial process follows international medical standards and best practices.
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in oncology, clinical pharmacology, gastroenterology, and internal medicine.